An open-label, randomized study comparing 3 years tamoxifen versus 3 years letrozole as continuation of adjuvant treatment of postmenopausal women with estrogen receptor positive and/or progesterone receptor positive early breast cancer who already completed 2 years adjuvant tamoxifen. A large Thai multicenter study
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2013
At a glance
- Drugs Letrozole (Primary) ; Tamoxifen
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms LOTUS
- 31 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ISRCTN record.
- 24 Dec 2005 New trial record.